HIV Infections, Sarcoma, Kaposi
Conditions
Keywords
Mitoxantrone, Acquired Immunodeficiency Syndrome
Brief summary
To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
Interventions
DRUGMitoxantrone hydrochloride
Sponsors
Lederle Laboratories
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have the following: * Biopsy proven Kaposi's sarcoma in advanced stages. * Positive HIV antibody, HIV culture or antigen capture or T4 cells \< 500 in a patient with AIDS risk factor. * Informed consent and availability for follow-up.
Exclusion criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Uncontrolled opportunistic infection. * Any medical, surgical or psychiatric condition which would constitute a contraindication to the use of mitoxantrone. Concurrent Medication: Excluded: * Zidovudine (AZT). Patients with the following are excluded: * Uncontrolled opportunistic infection. * Unable to give informed consent. * Any medical, surgical or psychiatric condition which would constitute a contraindication to the use of mitoxantrone. Prior Medication: Excluded: * More than one form of chemotherapy regimen. * Doxorubicin therapy \> 300 mg/m2. Prior Treatment: Excluded: * Previous therapy consisting of more than one modality of therapy (e.g., chemotherapy plus radiotherapy or more than one form of chemotherapy regimen.)
Countries
United States
Outcome results
None listed